Half-year report · Q2
4543.TEDINET S100UOKT
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥508.7bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥921.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥443.9bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥87.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥66.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥85.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥140.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥66.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥106.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.75T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.83T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.75T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥438.8bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥504.3bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.31T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.33T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.26T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.31T | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.33T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.26T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥194.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥100.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥146.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥53.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥38.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.5bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥36.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥65.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥62.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥30.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥42.57 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.5 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥33.63 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥42.56 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥71.47 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥33.62 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 75.0% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.1% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥132m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥13.2bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥306.3bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76.9bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥104.3bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥508.6bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥102.8bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥119m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥10.6bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥265.7bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥57.6bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥94.0bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥443.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥76.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 637
| Item | Context | Value | Unit |
|---|---|---|---|
| Other current assets ca IFRS | CurrentQuarterInstant | 32164000000 | JPY |
| Current assets IFRS | Prior1YearInstant | 722116000000 | JPY |
| Current assets IFRS | CurrentQuarterInstant | 679198000000 | JPY |
| Property plant and equipment IFRS | Prior1YearInstant | 415845000000 | JPY |
| Property plant and equipment IFRS | CurrentQuarterInstant | 412163000000 | JPY |
| Goodwill and intangible assets IFRS | Prior1YearInstant | 588225000000 | JPY |
| Goodwill and intangible assets IFRS | CurrentQuarterInstant | 546599000000 | JPY |
| Investments accounted for using equity method IFRS | Prior1YearInstant | 2410000000 | JPY |
| Investments accounted for using equity method IFRS | CurrentQuarterInstant | 2034000000 | JPY |
| Other financial assets nca IFRS | Prior1YearInstant | 36368000000 | JPY |
| Other financial assets nca IFRS | CurrentQuarterInstant | 39482000000 | JPY |
| Deferred tax assets IFRS | Prior1YearInstant | 19977000000 | JPY |
| Deferred tax assets IFRS | CurrentQuarterInstant | 25325000000 | JPY |
| Other non current assets nca IFRS | Prior1YearInstant | 46458000000 | JPY |
| Other non current assets nca IFRS | CurrentQuarterInstant | 47456000000 | JPY |
| Non current assets IFRS | Prior1YearInstant | 1109286000000 | JPY |
| Non current assets IFRS | CurrentQuarterInstant | 1073061000000 | JPY |
| Assets IFRS | Prior1YearInstant | 1831402000000 | JPY |
| Assets IFRS | CurrentQuarterInstant | 1752260000000 | JPY |
| Trade and other payables cl IFRS | Prior1YearInstant | 93770000000 | JPY |
| Trade and other payables cl IFRS | CurrentQuarterInstant | 93963000000 | JPY |
| Bonds and borrowings cl IFRS | Prior1YearInstant | 156870000000 | JPY |
| Bonds and borrowings cl IFRS | CurrentQuarterInstant | 15000000000 | JPY |
| Other financial liabilities cl IFRS | Prior1YearInstant | 7837000000 | JPY |
| Other financial liabilities cl IFRS | CurrentQuarterInstant | 7848000000 | JPY |
| Income taxes payable cl IFRS | Prior1YearInstant | 26467000000 | JPY |
| Income taxes payable cl IFRS | CurrentQuarterInstant | 27822000000 | JPY |
| Provisions cl IFRS | Prior1YearInstant | 213000000 | JPY |
| Provisions cl IFRS | CurrentQuarterInstant | 227000000 | JPY |
| Other current liabilities cl IFRS | Prior1YearInstant | 93992000000 | JPY |
| Other current liabilities cl IFRS | CurrentQuarterInstant | 86180000000 | JPY |
| Total current liabilities IFRS | Prior1YearInstant | 379152000000 | JPY |
| Total current liabilities IFRS | CurrentQuarterInstant | 231043000000 | JPY |
| Bonds and borrowings ncl IFRS | Prior1YearInstant | 74978000000 | JPY |
| Bonds and borrowings ncl IFRS | CurrentQuarterInstant | 159804000000 | JPY |
| Other financial liabilities ncl IFRS | Prior1YearInstant | 30824000000 | JPY |
| Other financial liabilities ncl IFRS | CurrentQuarterInstant | 29360000000 | JPY |
| Deferred tax liabilities IFRS | Prior1YearInstant | 3025000000 | JPY |
| Deferred tax liabilities IFRS | CurrentQuarterInstant | 2659000000 | JPY |
| Retirement benefit liability ncl IFRS | Prior1YearInstant | 5939000000 | JPY |
| Retirement benefit liability ncl IFRS | CurrentQuarterInstant | 6054000000 | JPY |
| Provisions ncl IFRS | Prior1YearInstant | 112000000 | JPY |
| Provisions ncl IFRS | CurrentQuarterInstant | 127000000 | JPY |
| Other non current liabilities ncl IFRS | Prior1YearInstant | 10279000000 | JPY |
| Other non current liabilities ncl IFRS | CurrentQuarterInstant | 9703000000 | JPY |
| Non current labilities IFRS | Prior1YearInstant | 125159000000 | JPY |
| Non current labilities IFRS | CurrentQuarterInstant | 207709000000 | JPY |
| Liabilities IFRS | Prior1YearInstant | 504311000000 | JPY |
| Liabilities IFRS | CurrentQuarterInstant | 438752000000 | JPY |
| Share capital IFRS | Prior1YearInstant | 38716000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |